Diffuse large B-cell lymphoma may take months to go from early to advanced stages, it may take years, or it may be possible to reach a cure for the disease after treatment without reaching advanced stages.
Diffuse large B-cell lymphoma is an extremely heterogeneous group of diseases. This means that the prognosis for patients with the disease is variable, with low-risk patients even achieving cure with chemotherapy alone, while high-risk patients may not respond to treatment and the disease progresses rapidly, reaching an advanced stage in a matter of months, with a very short survival period.
Therefore, for patients with diffuse large B-cell lymphoma, not only diagnosis but also prognostic stratification is required, and individualized treatment plans are selected according to the prognostic stratification. The intensity of the treatment regimen tends to be different for low-risk patients compared to high-risk patients.
Specific therapeutic agents include rituximab, cyclophosphamide, and vincristine, and high-risk patients need to undergo autologous stem cell transplantation or allogeneic stem cell transplantation. Specific diagnosis and treatment needs to be directed by a physician.